Research Information System
18th SIS World Congress on Breast Healthcare, Florida, United States Of America, 16 October 2014 - 19 October 2016, vol.2, no.2, pp.188, (Summary Text)
Introduction: Idiopathic Granulomatous Mastitis (IGM) is a rare benign inflammatory breast disese of unknown etiology. It may mimic breast carcinoma clinically and raadiologically. The treatment of IGM remains challenging. To our knowledge, this study is the largest series of Idiopathic Granulomatous Mastitis (IGM) to date.
AIMS: To report the largest series of IGM from Turkey, to investigate the contributory factors for the disease and review our experience of different therapeutic strategies.
METHODS: Between 2009 and 2014, 101 women with biopsy-proven granulomatous mastitis, managed by our mastitis team, were reviewed retrospectively. Demographic and clinical data, different treatment modalities, response to the treatment, recurrence, and the follow-up data were obtained from the medical records.
RESULTS: The mean age was 33,1+/- 5,7 years. The most common presenting symptom was a hard mass, which was detected in all of the patients. Currently, only 12 (11,9%) patients were resistant to the drug treatment. The rest of the patients had complete recovery. 40 (39,6%) patients had no recurrence during a mean follow-up period of 21 months (range:11-26 months) There was no significant association between smoking and the response to the treatment (p=0,6). There was no significant association between contraception and the resistance to the treatment (p=0,95). There was no significant association between the age and the resistance to the treatment (p=0,795).
CONCLUSIONS: IGM is a rare benign disease which usually affects women of childbearing age. Oral steroid theraphy is an effective treatment for IGM. However expectant management seems to be a rational choice.